PP176. PHARMACOGENETICS OF ACENOCOUMAROL - CYP2C9, CYP2C19, CYP1A2, CYP3A4/5 AND MDR1 GENE POLYMORPHISMS AND DOSE REQUIREMENTS
RADOSLAVA SARAEVA 1,3, I. Paskaleva 2, C. Eap 3, V. Ganev 1 1. Departement of Chemistry and Biochemistry, Medical University of Sofia Bulgaria 2. National Heart Hospital, Sofia Bulgaria; 3. Unite de Biochimie et Psycho-pharmacologie Clinique, Departement Universitaire de Psychiatrie Adulte, Prilly-Lausanne - Switzerland. e-mail: r_saraeva@yahoo.com
*Corresponding Author:
page: 126

Abstract

Acenocoumarol (AC) is a coumarin derivative, vitamin K antagonist, used in the anticoagulant therapy, having a narrow therapeutic index and a large pharmacokinetic and pharmacodynamic interindividual variability. This variability is due to genetic polymorphisms in the enzymes and transporters participating in its metabolism. Aim: To investigate the association between the AC dose requirements for achieving a target level of anticoagulation and allelic variants in the gene products are associated with its metabolism and transport: CYP2C9*2 and *3; CYP1A2*1F; CYP2C19*2 and CYP2C19*3; CYP3A4*1B; CYP3A5*3; MDR1 A61>G, MDR1 G2677>T and MDR1 C3435>T. Study design and methods: Our study included 119 Bulgarian patients treated with the oral anticoagulant AC for at least 3 months. They were separated in four groups according to their AC dose requirement: very low, low, medium and high. For detection of studied polymorphic variants a real time PCR was used. Results: CYP2C9 genotypes distribution analysis showed that the carriers of CYP2C9*1/*3, CYP2C9*2/*2 CYP2C9*2/*3 genotypes are more prevalent in the group of very low dose requirement of AC compared to the other three groups (?2=26.64, df=12, p= 0.009). The frequency of wild type genotype CYP2C9*1/*1 was predominant in the group of patients with high dose requirements (81.8%), compared to that in the groups of medium, low and very low dose requirements (64.7%, 61.3% and 26.7%). The distribution of other polymorphisms did not show significant difference between the four groups. Conclusion: The carriership of CYP2C9*2 or/and CYP2C9*3 allele in Bulgarian patients is associated with low dose requirement of AC.




Number 20
VOL. 20 (1), 2017
Number 19
VOL. 19 (2), 2016
Number 19
VOL. 19 (1), 2016
Number 18
VOL. 18 (2), 2015
Number 18
VOL. 18 (1), 2015
Number 17
VOL. 17 (2), 2014
Number 17
VOL. 17 (1), 2014
Number 16
VOL. 16 (2), 2013
Number 16
VOL. 16 (1), 2013
Number 15
VOL. 15 (2), 2012
Number 15
VOL. 15, 2012 Supplement
Number 15
Vol. 15 (1), 2012
Number 14
14 - Vol. 14 (2), 2011
Number 14
The 9th Balkan Congress of Medical Genetics
Number 14
14 - Vol. 14 (1), 2011
Number 13
Vol. 13 (2), 2010
Number 13
Vol.13 (1), 2010
Number 12
Vol.12 (2), 2009
Number 12
Vol.12 (1), 2009
Number 11
Vol.11 (2),2008
Number 11
Vol.11 (1),2008
Number 10
Vol.10 (2), 2007
Number 10
10 (1),2007
Number 9
1&2, 2006
Number 9
3&4, 2006
Number 8
1&2, 2005
Number 8
3&4, 2004
Number 7
1&2, 2004
Number 6
3&4, 2003
Number 6
1&2, 2003
Number 5
3&4, 2002
Number 5
1&2, 2002
Number 4
Vol.3 (4), 2000
Number 4
Vol.2 (4), 1999
Number 4
Vol.1 (4), 1998
Number 4
3&4, 2001
Number 4
1&2, 2001
Number 3
Vol.3 (3), 2000
Number 3
Vol.2 (3), 1999
Number 3
Vol.1 (3), 1998
Number 2
Vol.3(2), 2000
Number 2
Vol.1 (2), 1998
Number 2
Vol.2 (2), 1999
Number 1
Vol.3 (1), 2000
Number 1
Vol.2 (1), 1999
Number 1
Vol.1 (1), 1998

 

 


 About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact
 Copyright © Balkan Journal of Medical Genetics 2006